Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
NCT00037791
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
180
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Thrombocytopenia
Multiple Myeloma
Lymphoma, Malignant
Interventions
DRUG:
(PN-152,243)/PN-196,444
Sponsor
Pfizer